FINHUB Insights

PFE · Q1 FY25 · Jan 1 – Mar 30, 2025

Pfizer Q1 FY25: where the revenue came from and where it went

Pfizer Q1 FY25: revenue $13.7B (−8% year over year). Net profit $3B. Largest cohort US $8.4B. The whole income statement as a sankey diagram from the SEC filing.

Period
Jan 1 – Mar 30, 2025
Reported
May 5, 2025 10-Q
Sankey diagram of Pfizer's income statement for Q1 FY25: revenue of $13.7 billion splits into segments and flows out into costs, taxes and net profit.

Tap the diagram to enlarge · figures in billions of dollars

Revenue$13.7B −8% year over year
Gross profit$10.9B 79% margin
Operating profit$-3B -22% margin
Net profit$3B 22% margin

The numbers

All figures in billions of U.S. dollars, for Q1 FY25 (period ends Mar 30, 2025).
ItemValueShare of revenueYear over year
Revenue 13.7 100% −8%
US 8.4 61% −12%
International Developed Markets 3.2 23% −1%
International Emerging Markets 2.2 16% +0%
Cost of revenue−2.820%
Gross profit10.979% margin+2pp
SG&A−322%−1pp
Other−10.879%+0pp
Operating profit-3-22% margin+0pp
Net profit322%+1pp
Filing on EDGAR More quarters of PFE

Source of the numbers: structured XBRL data from the filing (10-Q). The diagram is generated automatically and checked against EDGAR before release. How we calculate it → About and methodology.

Older quarters